Sandoz manufactures high-impact medicines that bring savings to US patients and support the sustainability of the overall US healthcare system

Sandoz announced the US launch of its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, an AB-rated generic equivalent to AbbVie’s Combigan, to lower eye pressure in patients with ocular hypertension (high eye pressure). This prescription eyedrop is immediately available to patients via retail pharmacies.

Anyone can develop ocular hypertension, but certain groups are at higher risk, including but not limited to African Americans and Hispanics, people over age 40, people living with diabetes or high blood pressure, and people who are very myopic (near-sighted) and people who take long-term steroid medicines.4 It is important to treat high eye pressure before it causes damage to the optic nerve and vision loss.

“Fixed combinations of medicines to treat ocular hypertension can offer patients enhanced convenience, improved adherence, reduced exposure to preservatives, and cost savings,” said Keren Haruvi, President, Sandoz. “We developed this important generic eye treatment in-house to expand patient access to high-quality, more affordable eye care for millions of US patients.”

Sandoz is a leading provider of ophthalmic medicines in the US, with over 36 product families for the treatment of a wide range of eye diseases. The launch of generic brimonidine tartrate/timolol maleate combination eyedrops in the US expands the Sandoz ophthalmology portfolio, helping maintain its #1 position in the US generic ophthalmic space.